Navigation Links
Isis Pharmaceuticals to Present at The Wells Fargo 2010 Healthcare Conference
Date:6/16/2010

CARLSBAD, Calif., June 16 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Wells Fargo's 2010 Healthcare Conference on Wednesday, June 23, 2010 at 2:00 p.m. ET at the InterContinental Boston.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 22 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Obamas Healthcare Reform Bill and its Impact on the U.S. Healthcare Markets (Pharmaceuticals, Medical Devices and Health Insurance)
2. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
3. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
4. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
5. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
6. Alexza Pharmaceuticals to Present at Jefferies 2010 Global Life Sciences Conference
7. Hospira Announces Further Extension of Tender Offer for Shares of Javelin Pharmaceuticals
8. Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd.
9. Jazz Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
10. Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development
11. Shire Receives LIALDA(R) Paragraph IV Notice Letter From Zydus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017 Cardiology devices segment is anticipated to reach ... The Cardiology Devices segment is likely to create absolute $ ... 2018 over 2017. By the end of 2027, Cardiology Devices ... US$ 700 Mn, expanding at a CAGR of 18.4% over ... Asia Pacific reprocessed medical devices market in ...
(Date:4/19/2017)... , Tenn. and DALLAS , April ... EndoStim, Inc., announced that the first patients in ... the EndoStim device in the Lower Esophageal Sphincter Stimulation ... a minimally-invasive implantable device designed to provide long-term reflux ... neurostimulation. GERD affects nearly 65 million people ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting new patients ... in Lutz, FL. With the help of this highly-effective, yet convenient system, patients can ... more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical ... partners to help with process innovation in drug formulation and manufacturing. CoreRx ... with state-of-the-art analytical equipment in support of their development and manufacturing goals. ...
(Date:4/25/2017)... ... ... Back Pain Centers of America (BPC), which connects people searching for ... announces the launch of a new and proprietary customer relationship management (CRM) system named ... to help them with back or neck pain and helps to match them with ...
(Date:4/25/2017)... NJ (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed ... treatment of acute or chronic problems, I focus on preventative care with all my patients ... you have any questions, always feel free to contact my office and my trained staff ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency ... Series, Outliers in Writing, set to publish in summer 2017. , Dr. Bobrow, ... University of Arizona College of Medicine. He also serves as Medical Director for the ...
Breaking Medicine News(10 mins):